H.C. Wainwright reiterates PepGen stock rating on data outlook By Investing.com

H.C. Wainwright reiterated a Buy on PepGen with a $20 price target versus a $1.44 share price, implying substantial upside despite ongoing regulatory and clinical overhangs. The company continues to advance FREEDOM2/OLE dose escalation, with management indicating a DSMB update may cover 10 to 12.5 mg/kg and that cohort 2 is fully recruited, with data potentially in 2H 2026. Recent Q4 EPS also beat expectations at a $0.27 loss versus a $0.37 loss expected, but shares remain pressured by the FDA partial clinical hold.

Analysis

PEPG is starting to look less like a binary “data risk” story and more like a timing/positioning trade around the gap between biomarker interpretability and regulator sentiment. The key second-order issue is that if the splicing endpoint is as noisy as management argues, then near-term readouts should mechanically favor the active arm once dosing is high enough, because the placebo/background drift becomes a meaningful source of false negatives in small cohorts. That creates asymmetry into the next dose-escalation update: even a modestly clean safety package can re-rate the stock because investors are currently discounting the program as if the U.S. hold were a fundamental efficacy failure rather than a process problem.

The market is probably underappreciating the financing optionality embedded in the balance sheet. A clinical-stage name with this much cash relative to debt and a depressed equity value can survive multiple quarters of delay, which reduces dilution pressure and keeps management in control of trial pacing; that matters because the real risk is not immediate insolvency but the possibility that the program becomes a slow-motion confidence trap. If the next update confirms tolerability at 10-12.5 mg/kg, the stock could move sharply before efficacy data because the street will begin pricing a credible path to a cleaner U.S. restart.

The contrarian read is that consensus may be overfocusing on the hold while underweighting the catalytic power of a single coherent dataset. The setup favors a reflexive squeeze if management can show a dose-response and explain away the prior noise; however, if the 12.5 mg/kg cohort reproduces only marginal biomarker movement or any safety signal emerges across the escalated doses, the equity likely retraces quickly because the float is small and expectations are now anchored to a turnaround narrative rather than a clinical platform story.

Key Decisions for Investors

• Initiate a starter long in PEPG ahead of the next DSMB/safety update; structure as a tight-risk event trade with a 4-8 week horizon, targeting a 30-60% upside move if dose escalation is affirmed, and cutting if safety language widens the hold.
• For higher convexity, buy PEPG call spreads into the May 28 presentation / next catalyst window; this is best if implied volatility stays below the expected event premium, with upside skew to a potential re-rating on biomarker clarity.
• Avoid chasing size until the market digests whether the hold is truly procedural; if the stock pops on headlines, use strength to sell into 1-2 day momentum rather than assuming a durable trend until 12.5 mg/kg data are in hand.
• Watch for dilution risk in any further delay to the 2H 2026 data path; if management needs to bridge beyond current cash burn assumptions, reassess the long as the downside shifts from binary clinical to financing overhang.
• Relative-value idea: pair long PEPG against a basket of other small-cap DM1/rare-disease names with less cash runway, on the view that PEPG’s balance sheet and near-term catalyst cadence make it the cleaner survivor if the modality remains viable.